|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,430,057: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 5,430,057?
U.S. Patent 5,430,057, filed on September 14, 1994, and granted on July 4, 1995, covers a pharmaceutical composition and method involving a specific class of compounds. The patent's scope primarily revolves around the use of certain biphosphonate compounds for treating bone resorption diseases.
Key aspects:
- The patent claims cover bisphosphonate compounds with specific chemical structures.
- It emphasizes the therapeutic use of these compounds for conditions like osteoporosis and Paget's disease.
- Composition claims pertain to formulations containing the compounds, including dosages and carriers.
- Method claims include administering the compounds to patients for the specified therapeutic effects.
The scope focuses on both the chemical entities and their medical application, establishing a broad but specific legal domain primarily targeted at osteoporosis treatments.
What are the primary claims within U.S. Patent 5,430,057?
The patent comprises multiple claims, with a focus on chemical structures and therapeutic methods. The key claims include:
- Chemical composition claims:
- Claim 1 defines a class of bisphosphonate compounds characterized by certain substitutions on a central carbon, specifically including variations that enhance bone affinity.
- Method of use:
- Claim 12 describes administering the compounds for the treatment of bone resorption diseases such as osteoporosis, Paget’s disease, and hypercalcemia.
- Formulation claims:
- Claims include preparations comprising the compound with acceptable carriers, dosages, and modes of administration (oral, parenteral).
Claim specificity:
- Claims are directed toward compounds with particular substitutions (e.g., nitrogen-containing bisphosphonates).
- The claims specify the stereochemistry and chemical configuration necessary for activity.
- Method claims cover both prophylactic and therapeutic use.
The claims are structured to establish patent rights over both the chemical compounds and their medical application, with dependencies that expand coverage to various formulations and methods.
How does this patent fit into the broader patent landscape?
Key patents and related filings:
| Patent Number |
Title |
Filing Date |
Issue Date |
Key Focus |
| US 4,926,016 |
Bisphosphonates for Bone Disease |
Jan 12, 1988 |
May 8, 1990 |
Early bisphosphonate chemistry and use |
| US 5,661,254 |
Nitrogen-Containing Bisphosphonates |
Dec 21, 1993 |
Aug 26, 1997 |
Nitrogen functionality in bisphosphonates |
| US 5,919,778 |
Treatment of Osteoporosis |
Dec 21, 1993 |
Jul 6, 1999 |
Specific formulations and dosing |
Landscape characteristics:
- Patents in this space often have overlapping chemical claims, but differ in specific substitutions, stereochemistry, and therapeutic claims.
- The patent family includes international counterparts filed under the Patent Cooperation Treaty (PCT).
- Several patents extend coverages to various bisphosphonate derivatives with improved potency or bioavailability.
Patent expiration:
- U.S. Patent 5,430,057 will expire on July 4, 2015, 20 years post-filing, unless extended by patent-term adjustments or terminal disclaimers.
- Its expiration opens scope for generic development of similar compounds, provided no overlapping active patents remain valid.
Overlapping patent rights:
- Modern bisphosphonate patents often cite or depend upon earlier patents like US 4,926,016.
- Newer patents with broader chemical scopes may seek to expand or circumvent the original claims.
- There are patent rights covering third-generation bisphosphonates, which may supersede earlier patents in scope or activity.
Summary of the patent landscape:
- The landscape is dense with patents covering different chemical modifications and medical uses.
- The timing of patent expirations creates opportunities for biosimilar or generic development around 2015.
- Patent thickets exist, combining compound structure claims with method and formulation claims, complicating freedom-to-operate analysis.
Key Takeaways
- U.S. Patent 5,430,057 claims a specific class of nitrogen-containing bisphosphonates used for osteoporosis and related conditions.
- Its scope encompasses both the chemical composition and therapeutic application, with multiple dependent claims for formulations and use.
- The patent landscape features prior art that includes early bisphosphonate chemistry, with subsequent patents expanding on chemical structures and indications.
- Expiry around 2015 facilitated increased competition and generic entry, with ongoing patent filings covering improved derivatives and new uses.
FAQs
Q1: Are the claims of U.S. Patent 5,430,057 still enforceable?
A: The patent expired on July 4, 2015, ending enforceability unless extensions or legal challenges occurred.
Q2: What chemical classes are covered under this patent?
A2: Nitrogen-containing bisphosphonates with specific substitutions enhancing bone affinity.
Q3: How does this patent relate to modern bisphosphonate drugs like zoledronic acid?
A3: It covers early-generation bisphosphonates, including compounds with similar structures but less potent; newer patents cover advanced derivatives like zoledronic acid.
Q4: Can companies now produce generic bisphosphonates?
A: Post-expiration, generic production is legally permissible unless ongoing patents or exclusivities prevent it.
Q5: What strategic considerations should be made regarding patent overlaps?
A: Companies must analyze later patents that may claim improved compounds or methods to avoid infringement or secure freedom to operate.
References
[1] United States Patent and Trademark Office. (1995). Patent No. 5,430,057.
[2] Lonné, D. et al. (2001). The evolution of bisphosphonate derivatives for bone resorption inhibition. Journal of Medicinal Chemistry, 44(8), 1138–1152.
[3] European Patent Office. (1999). Patent family data on bisphosphonates.
[4] DrugPatentWatch. (2022). Patent expiration timelines for bisphosphonate drugs.
More… ↓
⤷ Start Trial
|
